4th Quarter - Amendment

CAPITOL HILL CONSULTING GROUP for ASTELLAS PHARMA US

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 14, 2009 $30,000 Replaced
4th Quarter - Amendment Jan 16, 2009 $30,000 Replaced
4th Quarter - Amendment (this page) Dec 10, 2009 $30,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month

Foreign entity interest: Astellas Pharma, Inc., based in Tokyo, Japan, the owner of Astellas Pharma US as identified in its LD-1, has an interest in each issue on which Astellas Pharma US lobbies and would benefit from the specific desired outcome in the matter described above.

LobbyistCovered position, as disclosed
BILL K BREWSTER —
AMANDA HILL —
STEVEN E IRIZARRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3560 (110th), S.Res. 454 (110th), S. 2313 (110th), H.R. 6432 (110th), H.Res. 988 (110th), H.R. 3697 (110th)

Medicare/Medicaid MMM

Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; , Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, S. 2320 and H.R. 3282 , the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005; S. 3560, QI Program Supplemental Funding Act of 2008 -- the QI bill included language to protect critical medications under Part D originally in H.R. 6331/S. 1887.

Foreign entity interest: Astellas Pharma, Inc., based in Tokyo, Japan, the owner of Astellas Pharma US as identified in its LD-1, has an interest in each issue on which Astellas Pharma US lobbies and would benefit from the specific desired outcome in the matter described above.

LobbyistCovered position, as disclosed
BILL K BREWSTER —
AMANDA HILL —
STEVEN E IRIZARRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3560 (110th), S. 1951 (110th), H.R. 6331 (110th), H.R. 3700 (110th), S. 1887 (110th), H.R. 3282 (110th), S. 2320 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.